Absence of SARS-CoV-2 (COVID-19 virus) within the IVF laboratory using strict patient screening and safety criteria

Is there a risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral exposure and potential cross-contamination from follicular fluid, culture media and vitrification solution within the IVF laboratory using strict patient screening and safety measures? This was a prospective clinic...

Full description

Saved in:
Bibliographic Details
Published in:Reproductive biomedicine online 2021-06, Vol.42 (6), p.1067-1074
Main Authors: Rajput, Sandeep K., Khan, Shaihla A., Goheen, Benjamin B., Engelhorn, Heidi J., Logsdon, Deirdre M., Grimm, Courtney K., Kile, Rebecca A., West, Rachel C., Yuan, Ye, Schoolcraft, William B., McCormick, Sue, Krisher, Rebecca L., Swain, Jason E.
Format: Article
Language:English
Subjects:
Blastocyst
COVID-19
Cryo-storage
Follicular fluid
Oocyte
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Is there a risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral exposure and potential cross-contamination from follicular fluid, culture media and vitrification solution within the IVF laboratory using strict patient screening and safety measures? This was a prospective clinical study. All women undergoing transvaginal oocyte retrieval were required to have a negative SARS-CoV-2 RNA test 3–5 days prior to the procedure. Male partners were not tested. All cases used intracytoplasmic sperm injection (ICSI). The first tube of follicular fluid aspirated during oocyte retrieval, drops of media following removal of the embryos on day 5, and vitrification solution after blastocyst cryopreservation were analysed for SARS-CoV-2 RNA. In total, medium from 61 patients, vitrification solution from 200 patients and follicular fluid from 300 patients was analysed. All samples were negative for SARS-CoV-2 viral RNA. With stringent safety protocols in place, including testing of women and symptom-based screening of men, the presence of SARS-CoV-2 RNA was not detected in follicular fluid, medium or vitrification solution. This work demonstrates the possibility of implementing a rapid laboratory screening assay for SARS-CoV-2 and has implications for safe laboratory operations, including cryostorage recommendations.
ISSN:1472-6483
1472-6491
DOI:10.1016/j.rbmo.2021.03.005